PolarityTE — Investor Presentation (April 2017)
18 slides from PolarityTE's investor presentation, Apr 17, 2017
Slide 1: PolarityTE, Inc.
PolarityTE™, Inc. 615 Arapeen Drive, Suite 102 Salt Lake City, UT 84108 www.PolarityTE.com [email protected] (385) 237-2365
Slide 2: Forward Looking Statements
rwa ooking Statemen FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements and projections. The company makes no express or implied representation or warrant as to the completeness of this information or, in the case of projections, as to their attainability or the accuracy
Slide 3: Opportunity, Technological Advantage, Strategy, Pipeline
OPPORTUNITY ) Clinical stage regenerative medicine company with a platform technology able to create functional / tissue, beginning with regenerated skin that grows all layers, glands, and hair TECHNOLOGICAL ADVANTAGE § Autologous tissue with its stem cell niche and supporting elements to regenerate
Slide 4: The PolarityTEAM — Management
The PolarityTEAM — Management Denver Lough, MD, PhD Edward (Ned) Swanson, MD John Stetson Chairman, President, CEO, Chief Scientific Executive Vice President, COO, Director Executive Vice President, CFO, Officer * Former Resident in Plastic and Reconstructive Director + Former Resident in Plastic an
Slide 5: The PolarityTEAM — Board of Directors
The PolarityTEAM — Board of Directors Denver Lough, MD, PhD Steve Gorlin Chairman, President, CEO, Chief Scientific Officer Director + Former Resident in Plastic and Reconstructive + Regenerative Medicine and Biotech Pioneer: Surgery at Johns Hopkins Founder of Hycor Biomedical, Inc. (acquired by +
Slide 6: Global Regenerative Med and Wound Care Markets
Global Regenerative Med and nd Care Markets ® Current markets remain untapped with redundant products ‘conan ti Wortwide Prevalence of and no autologous (patient’s own tissue/cells) tissue Wounditypes201te2020 engineering Complicated skin cancer Melanoma ® The global market for tissue engineering is
Slide 7: A Massive Market Saturated with Stagnant Products
Integra Bilayer Wound Matrix GRAFTJACKET Epifix Grafix Apligraf Allograft Skin Epicel Fundamental Principles and Building Blocks for True Functional Skin Regeneration Integra LifeSciences Wright Medical Group MiMedx Osiris Organogenesis Allosource, MTF, Others Vericel No No Dead Yes Yes Yes Yes Auto
Slide 8: Current Therapies: Limitations
Current Therapies: Limitations ® No Cells: Acellular scaffolds lack the innate ability to regenerate tissue and rely on surrounding tissue in-growth and ultimately secondary skin grafts for definitive coverage Allogeneic/Xenogeneic Cells: Another person’s cells or animal cells will always reject and
Slide 9: The PolarityTE Platform Technology
The PolarityTE™ Platform Technology Discovered through careful observation of tissue regeneration in real-time, the PolarityTE™ Platform Technology has proved its regenerative capacity in ps preclinical models in SKIN, bone, se i . Vessels/Capillaries muscle, fat, cartilage, nerve, blood . vessels,
Slide 10: The PolarityTE Advantage
he PolarityTE Advantag 2 — Autologous: The immune system is highly complex and evolved to recognize anything that isn’t “self”. Our foundation is built on using autologous tissue, avoiding allogeneic tissue rejection and foreign body reactions. Autologous tissue immediately removes 99% of the compet
Slide 11: The PolarityTE Launch Product - SkinTE
The PolarityTE Launch Product - SkinTE Qo | Patient Biopsy: Acquire patient’s skin Polarization: Natural skin layer formation, including hair and appendages Apply regenerated construct back to the best known bioreactor — the patient Imprint cells in laboratory in 3D system using our platform technol
Slide 12: Development Pipeline
Development Pipeline Qe > evr > a
Slide 13: Pathway and Timelines
rat Pathway, and Timelines Manufacturing Optimization December 2017 > Human Pilot Trial in Cranial Defects Product Registration and Market Entry ae January 2018 a22018 >
Slide 14: Burn Market Commercialization Strategy
Burn Market Commercialization Strategy ® National Landscape: 126 burn centers nationwide, creating a straightforward scale-up plan ® Key Decision Makers: Burn Center treatments dictated by Burn Center Directors ® Leaders in the Field on PolarityTE Team: Chief Clinical Officer Dr. Stephen Milner, For
Slide 15: PolarityTE Capitalization
a PolarityTE ——= NASDAQ: COOL Converted Common Stock Options Preferred Stock www.PolarityTE.com Series A 792,933 Series B 801,820 Series C 410,247 Series D 157,776 Series E 7,050,000 Common Stock 4,976,768 Stock Options 700,000* Total** 14,189,544 700,000 344,
Slide 16: A regenerative medicine company with a proprietary platform technology
A regenerative medicine company with a revolutionary proprietary platform technology capable of regenerating fully functional tissue across a wide spectrum of tissues — skin, bone, muscle, cartilage, nerve, liver, and more The proprietary platform technology provides a spring board for repeated prod
Slide 17: Slide 17
Slide 18: Thank You
Thank You PolarityTE™, Inc. NASDAQ: COOL 615 Arapeen Drive Salt Lake City, UT 84108 (385) 237-2365 www.PolarityTE.com ParadigmShift @PolarityTE.com